$AQST
Aquestive Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000114036120024555 Filed on November 04, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $7.149M $8.260M $16.42M
YoY Change -56.46% -33.48% -2.41%
Cost Of Revenue $2.788M $2.978M $6.792M
YoY Change -58.95% -35.86% 41.8%
Gross Profit $4.361M $5.282M $9.627M
YoY Change -54.7% -32.06% -20.04%
Gross Profit Margin 61.0% 63.95% 58.63%
Selling, General & Admin $15.58M $11.80M $16.47M
YoY Change -5.4% -13.93% -11.93%
% of Gross Profit 357.26% 223.46% 171.08%
Research & Development $4.430M $7.260M $3.060M
YoY Change 44.77% 43.39% -46.13%
% of Gross Profit 101.58% 137.45% 31.79%
Depreciation & Amortization $1.100M $714.0K $770.0K
YoY Change 42.86% 2.73% 1.32%
% of Gross Profit 25.22% 13.52% 8.0%
Operating Expenses $20.01M $19.06M $26.32M
YoY Change -23.98% -18.6% -9.77%
Operating Profit -$15.65M -$13.78M -$16.70M
YoY Change -6.27% 25.26% -2.55%
Interest Expense -$4.720M $2.778M -$2.730M
YoY Change 72.89% 4.75% 71.7%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.37M -$16.55M -$12.64M
YoY Change 61.16% -10.11% -9.33%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.37M -$16.55M -$12.64M
YoY Change 61.19% -10.11% -9.38%
Net Earnings / Revenue -284.91% -200.38% -76.96%
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$602.1K -$0.49 -$477.9K
COMMON SHARES
Basic Shares Outstanding 33.62M 33.62M shares 25.04M
Diluted Shares Outstanding 33.62M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.81M $17.06M $49.33M
YoY Change -35.52% -18.41% -18.6%
Cash & Equivalents $31.81M $17.06M $49.33M
Short-Term Investments
Other Short-Term Assets $3.400M $3.390M $3.000M
YoY Change 13.33% 25.09% 78.57%
Inventory $2.461M $3.242M $2.859M
Prepaid Expenses
Receivables $6.960M $7.990M $13.13M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $44.63M $31.68M $68.31M
YoY Change -34.68% -16.75% -7.93%
LONG-TERM ASSETS
Property, Plant & Equipment $6.873M $7.728M $9.726M
YoY Change -29.33% -25.34% -20.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.836M $287.0K $286.0K
YoY Change 2639.86% 18.6% 19.67%
Total Long-Term Assets $18.26M $18.74M $10.17M
YoY Change 79.63% 74.19% -19.64%
TOTAL ASSETS
Total Short-Term Assets $44.63M $31.68M $68.31M
Total Long-Term Assets $18.26M $18.74M $10.17M
Total Assets $62.88M $50.42M $78.48M
YoY Change -19.87% 3.29% -9.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.089M $9.169M $12.27M
YoY Change -42.24% -35.44% -39.94%
Accrued Expenses $8.569M $6.450M $5.475M
YoY Change 56.51% 33.54% -23.91%
Deferred Revenue $693.0K $722.0K $806.0K
YoY Change -14.02% -13.53% 11.79%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.580M $1.750M $0.00
YoY Change -100.0%
Total Short-Term Liabilities $21.10M $18.37M $18.56M
YoY Change 13.74% -8.38% -43.69%
LONG-TERM LIABILITIES
Long-Term Debt $34.33M $60.35M $60.34M
YoY Change -43.11% 0.95% 41.64%
Other Long-Term Liabilities $1.945M $8.220M $1.360M
YoY Change 43.01% 138.26% 11.48%
Total Long-Term Liabilities $1.945M $68.57M $1.360M
YoY Change 43.01% 8.45% -96.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.10M $18.37M $18.56M
Total Long-Term Liabilities $1.945M $68.57M $1.360M
Total Liabilities $111.4M $86.94M $84.60M
YoY Change 31.65% 4.4% 10.2%
SHAREHOLDERS EQUITY
Retained Earnings -$186.3M -$165.9M -$130.5M
YoY Change 42.75% 40.78% 112.58%
Common Stock $35.00K $34.00K $34.00K
YoY Change 2.94% 36.0% 36.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$48.50M -$36.52M -$6.122M
YoY Change
Total Liabilities & Shareholders Equity $62.88M $50.42M $78.48M
YoY Change -19.87% 3.29% -9.64%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$20.37M -$16.55M -$12.64M
YoY Change 61.19% -10.11% -9.38%
Depreciation, Depletion And Amortization $1.100M $714.0K $770.0K
YoY Change 42.86% 2.73% 1.32%
Cash From Operating Activities -$13.51M -$8.320M -$10.57M
YoY Change 27.81% -43.75% 276.16%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$40.00K -$80.00K
YoY Change 200.0% -55.56% -83.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$240.0K -$40.00K -$80.00K
YoY Change 200.0% -55.56% -83.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.49M 0.000 39.07M
YoY Change -27.08% -100.0% -48937.5%
NET CHANGE
Cash From Operating Activities -13.51M -8.320M -10.57M
Cash From Investing Activities -240.0K -40.00K -80.00K
Cash From Financing Activities 28.49M 0.000 39.07M
Net Change In Cash 14.74M -8.360M 28.42M
YoY Change -48.14% 568.8% -940.83%
FREE CASH FLOW
Cash From Operating Activities -$13.51M -$8.320M -$10.57M
Capital Expenditures -$240.0K -$40.00K -$80.00K
Free Cash Flow -$13.27M -$8.280M -$10.49M
YoY Change 26.5% -43.67% 352.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
112000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9169000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12274000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
17749000
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15237000
CY2019Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
9094000
CY2020Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
6659000
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1174000
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1655000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38044000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40171000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129336000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124318000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1739000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1422000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1810000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1420000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1702000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1823000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5200000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1427000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5052000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1870000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
264000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
124000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
58000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
39000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1338000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1758000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2363236
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4660860
CY2020Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
1482000
CY2019Q4 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
1360000
CY2019Q4 us-gaap Assets
Assets
78479000
aqst Increase Decrease In Offering Costs Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
237000
CY2020Q3 us-gaap Assets
Assets
50423000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
68314000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
31684000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17064000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20914000
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"><tr><td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Note 2.</td><td style="width: auto; vertical-align: top;"><div style="color: rgb(0, 0, 0); font-weight: bold;">Basis of Presentation</div></td></tr></table><div><br /></div><div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 18pt;">The accompanying interim unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes for the fiscal year ended December 31, 2019 included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 11, 2020 (the &#8220;2019 Annual Report on Form 10-K&#8221;). As included herein, the condensed consolidated balance sheet as of December 31, 2019 is derived from the audited consolidated financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results of interim periods have been included. The accompanying financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying unaudited condensed financial statements.</div><div><br /></div><div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 18pt;">Any reference in these notes to applicable guidance refers to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</div></div>
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49326000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17064000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-32262000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-39685000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49326000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60599000
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33562885
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33619796
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33619796
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33562885
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
34000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18412000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16551000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53610000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35415000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-591000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3694000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4348000
CY2020Q3 us-gaap Depreciation
Depreciation
714000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2288000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2337000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5154000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4416000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
806000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
722000
CY2019Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
4363000
CY2020Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8922000
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4643000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10176000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2978000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13569000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
22041000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
23420000
us-gaap Costs And Expenses
CostsAndExpenses
78954000
us-gaap Costs And Expenses
CostsAndExpenses
65947000
CY2019Q3 us-gaap Depreciation
Depreciation
695000
us-gaap Depreciation
Depreciation
2127000
us-gaap Depreciation
Depreciation
2143000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.15
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3758000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4129000
aqst Warrants Issued In Connection With Long Term Debt
WarrantsIssuedInConnectionWithLongTermDebt
0
aqst Increase Decrease In Offering Costs Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
162000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
50000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
50000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
153000
CY2020Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
115000
CY2020Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2867000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2867000
CY2020Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
50000
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2752000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2714000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4896000
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4896000
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35415000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53610000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16551000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18412000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5632000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2573000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-5082000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
3887000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-738000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1317000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
383000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1029000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7101000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2778000
us-gaap Interest Expense
InterestExpense
6515000
CY2019Q3 us-gaap Interest Expense
InterestExpense
2652000
us-gaap Interest Expense
InterestExpense
8296000
us-gaap Interest Paid Net
InterestPaidNet
6562000
us-gaap Interest Paid Net
InterestPaidNet
5153000
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
519000
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
858000
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1153000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1244000
CY2020Q3 us-gaap Inventory Net
InventoryNet
3242000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2859000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
us-gaap Investment Income Interest
InvestmentIncomeInterest
128000
us-gaap Investment Income Interest
InvestmentIncomeInterest
565000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
138000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
944000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1635000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
424000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
266000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
565000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5346000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
565000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1295000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1287000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78479000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50423000
CY2020Q3 us-gaap Liabilities
Liabilities
86942000
CY2019Q4 us-gaap Liabilities
Liabilities
84601000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18373000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18555000
CY2019Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0
CY2020Q3 us-gaap Loans Payable Current
LoansPayableCurrent
1750000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
70000000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
14000000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10500000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
17500000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3500000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
24500000
CY2020Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
60346000
CY2019Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
60338000
CY2013Q3 us-gaap Loss Contingency Number Of Defendants
LossContingencyNumberOfDefendants
6
us-gaap Loss Contingency Claims Settled Number
LossContingencyClaimsSettledNumber
3
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
4
CY2020Q3 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
3
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49635000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31947000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-16551000
us-gaap Net Income Loss
NetIncomeLoss
-53610000
us-gaap Net Income Loss
NetIncomeLoss
-35415000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-18412000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
62000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-20472000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-16530000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2334000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14726000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-577000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-281000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10527000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-34000
us-gaap Operating Lease Payments
OperatingLeasePayments
1255000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.169
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3711000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3047000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
664000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
409000
us-gaap Operating Lease Cost
OperatingLeaseCost
1228000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3609000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42764000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11002000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27247000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13781000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-76000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-34000
CY2020Q3 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
1872000
CY2019Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
4363000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
287000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
286000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
543000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
284000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2944000
CY2019Q3 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
2944000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
96000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2723000
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2415000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
3918000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
577000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3388000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2999000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
70000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
CY2019Q3 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
13110000
CY2019Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37295000
CY2019Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1821000
CY2020Q3 aqst Cumulative Royalty Receivable
CumulativeRoyaltyReceivable
7000000
CY2019Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
37835000
CY2019Q4 us-gaap Professional Fees
ProfessionalFees
540000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47899000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47770000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7728000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9726000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
140000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
66000
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Repayments Of Debt
RepaymentsOfDebt
50000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17517000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5063000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15461000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7260000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165889000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130474000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
36190000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
38700000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12418000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8260000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-6056000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-34459000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-20829000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-21388000
aqst Increase Decrease In Capital Expenditures Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses
152000
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13714000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40310000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11803000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47868000
us-gaap Share Based Compensation
ShareBasedCompensation
5052000
us-gaap Share Based Compensation
ShareBasedCompensation
5199000
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8050000
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8050000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
132000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
73000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-36519000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6122000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10080000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-24657000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">(B) Use of Estimates</div><div><br /></div><div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 18pt;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and contingent liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&#160; Significant items subject to estimates and assumptions include allowances for rebates from proprietary product sales, the allowance for sales returns, the useful lives of fixed assets, valuation of share-based compensation and contingencies.</div></div>
us-gaap Variable Lease Cost
VariableLeaseCost
255000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
89000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33592846
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33619379
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24992229
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25031478
aqst Increase Decrease In Capital Expenditures Included In Accounts Payable And Accrued Expenses
IncreaseDecreaseInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses
290000
aqst Accounts Receivable Allowances Provision Related To Sales
AccountsReceivableAllowancesProvisionRelatedToSales
3996000
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Aquestive Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001398733
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33619796
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 aqst Accounts Receivable Allowances And Accruals Trade And Other Receivables Net
AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet
277000
CY2019Q4 aqst Accounts Receivable Allowances And Accruals Trade And Other Receivables Net
AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet
203000
aqst Accounts Receivable Allowances Credits And Payments
AccountsReceivableAllowancesCreditsAndPayments
3441000
CY2019Q4 aqst Accounts Receivable Allowances And Accruals
AccountsReceivableAllowancesAndAccruals
1377000
CY2020Q3 aqst Accounts Receivable Allowances And Accruals
AccountsReceivableAllowancesAndAccruals
1932000
CY2019Q4 aqst Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses
AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses
1174000
CY2020Q3 aqst Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses
AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses
1655000
CY2020Q3 aqst Revenue From Contracts With Customers Number Of Sources Of Revenue
RevenueFromContractsWithCustomersNumberOfSourcesOfRevenue
4
aqst Invoices Payable Term
InvoicesPayableTerm
P75D
CY2020Q3 aqst Trade And Other Receivables Net
TradeAndOtherReceivablesNet
7990000
CY2019Q4 aqst Trade And Other Receivables Net
TradeAndOtherReceivablesNet
13130000
CY2020Q3 aqst Finite Lived Intangible Assets Net And Other Assets
FiniteLivedIntangibleAssetsNetAndOtherAssets
7402000
CY2019Q4 aqst Finite Lived Intangible Assets Net And Other Assets
FiniteLivedIntangibleAssetsNetAndOtherAssets
439000
aqst Warrants Issued In Connection With Long Term Debt
WarrantsIssuedInConnectionWithLongTermDebt
6800000
CY2019Q4 aqst Cumulative Royalty Receivable
CumulativeRoyaltyReceivable
0
aqst Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
0
CY2020Q3 aqst Number Of Proprietary Products Internally Developed
NumberOfProprietaryProductsInternallyDeveloped
1
CY2019Q3 aqst Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights
NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights
66082000
CY2020Q3 aqst Number Of Operating Leases
NumberOfOperatingLeases
3
CY2020Q3 aqst Working Capital Deficit
WorkingCapitalDeficit
13311000
CY2019Q3 aqst Additional Fund Amount
AdditionalFundAmount
52226000
CY2019Q4 aqst Adjustments To Additional Paid In Capital Warrant Exercise
AdjustmentsToAdditionalPaidInCapitalWarrantExercise
1821000
CY2020Q3 aqst Inventory Packing Material Gross
InventoryPackingMaterialGross
1231000
CY2019Q4 aqst Inventory Packing Material Gross
InventoryPackingMaterialGross
1096000
CY2020Q3 aqst Number Of States In The Antitrust Litigation
NumberOfStatesInTheAntitrustLitigation
41
aqst Number Of Patents
NumberOfPatents
2

Files In Submission

Name View Source Status
0001140361-20-024555-index-headers.html Edgar Link pending
0001140361-20-024555-index.html Edgar Link pending
0001140361-20-024555.txt Edgar Link pending
0001140361-20-024555-xbrl.zip Edgar Link pending
aqst-20200930.xml Edgar Link completed
aqst-20200930.xsd Edgar Link pending
aqst-20200930_cal.xml Edgar Link unprocessable
aqst-20200930_def.xml Edgar Link unprocessable
aqst-20200930_lab.xml Edgar Link unprocessable
aqst-20200930_pre.xml Edgar Link unprocessable
brhc10016591_10q.htm Edgar Link pending
brhc10016591_ex31-1.htm Edgar Link pending
brhc10016591_ex31-2.htm Edgar Link pending
brhc10016591_ex32-1.htm Edgar Link pending
brhc10016591_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending